Company Overview and News

Japanese firms face tough choices as U.S.-China trade war drags on

Many Japanese businesses caught in the crossfire of the U.S.-China trade war are facing an unsavory dilemma: Either make massive changes to how their products are assembled or bide their time until a compromise between the world’s two largest economies is reached.
DKILF DKILY 3636 6367

Japan’s largest sake exporter eyes even larger slice of international market

The new boss of Takara Holdings Inc., Japan’s biggest sake-supplier to overseas markets, wants to make the rice-based alcohol as popular as wine.
2531 3636 TKHIY

Japanese Sake Maker May Buy U.S. Firms to Set New Sales Records - Bloomberg

2018-08-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2531 3636 TKHIY

Japan's tiny sharing economy still in its infancy

2018-07-25 reuters
TOKYO (Reuters) - Japan’s sharing economy made up less than a 10th of a percent of nominal gross domestic product in 2016, research showed on Wednesday, in a sign the sector remains very much in its infancy.
3636 9984 SFTBF SFTBY

Tokyo expresses concern as U.S. announces fresh tariffs on China in escalating trade war

U.S. Trade Representative Robert Lighthizer on Tuesday proposed an additional $200 billion in tariffs on Chinese goods, rattling financial markets and setting off fears across the globe that the worst may be yet to come in the ongoing trade dispute between the world’s two largest economies.

Japanese firms shift to clean energy despite state’s enduring commitment to nuclear power

As Japan’s government clings to nuclear power even after the Fukushima crisis, the private sector is moving ahead with greater use of renewables to power their operations amid growing international awareness of climate change.

Drone deliveries ready to soar in Japan but lingering issues likely to keep post office in business

A drone carrying a package sails through the air, touching down to make a delivery right on a customer’s doorstep.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...